Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1601822rdf:typepubmed:Citationlld:pubmed
pubmed-article:1601822lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:1601822lifeskim:mentionsumls-concept:C0026986lld:lifeskim
pubmed-article:1601822lifeskim:mentionsumls-concept:C0008625lld:lifeskim
pubmed-article:1601822lifeskim:mentionsumls-concept:C0008626lld:lifeskim
pubmed-article:1601822lifeskim:mentionsumls-concept:C0021943lld:lifeskim
pubmed-article:1601822lifeskim:mentionsumls-concept:C1517961lld:lifeskim
pubmed-article:1601822pubmed:issue1lld:pubmed
pubmed-article:1601822pubmed:dateCreated1992-7-15lld:pubmed
pubmed-article:1601822pubmed:abstractTextEvidence suggests that prognosis in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML) depends more on karyotype than on formal classification as either MDS or AML according to the French-American-British (FAB) system. We provide further evidence of overlap between these two entities, reporting 4 patients who presented with either inv(16) (p13q22), del(16) (q22), or t(8;21) despite an FAB diagnosis of MDS rather than the diagnosis of AML with which these abnormalities are generally associated. In 3 patients, disease was relatively long-standing (3-10 months) prior to diagnosis, suggesting that the association between MDS and these cytogenetic abnormalities may not merely reflect a transient phenomenon. Two patients with inv(16) and the MDS subtype refractory anemia with excess blasts in transformation (RAEB-t) received AML-type chemotherapy as did a patient with t(8;21) and RAEB-t. All entered CR paralleling the high CR rate seen in patients with AML and these abnormalities. Our data support the concept that MDS and AML may be different manifestations of the same disease.lld:pubmed
pubmed-article:1601822pubmed:languageenglld:pubmed
pubmed-article:1601822pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1601822pubmed:citationSubsetIMlld:pubmed
pubmed-article:1601822pubmed:statusMEDLINElld:pubmed
pubmed-article:1601822pubmed:issn0886-0238lld:pubmed
pubmed-article:1601822pubmed:authorpubmed-author:EsteyEElld:pubmed
pubmed-article:1601822pubmed:authorpubmed-author:FreireichE...lld:pubmed
pubmed-article:1601822pubmed:authorpubmed-author:KeatingMMlld:pubmed
pubmed-article:1601822pubmed:authorpubmed-author:O'BrienSSlld:pubmed
pubmed-article:1601822pubmed:authorpubmed-author:BeranMMlld:pubmed
pubmed-article:1601822pubmed:authorpubmed-author:CorkAAlld:pubmed
pubmed-article:1601822pubmed:authorpubmed-author:TrujilloJ MJMlld:pubmed
pubmed-article:1601822pubmed:authorpubmed-author:KantarjianHHlld:pubmed
pubmed-article:1601822pubmed:authorpubmed-author:StassSSlld:pubmed
pubmed-article:1601822pubmed:issnTypePrintlld:pubmed
pubmed-article:1601822pubmed:volume6lld:pubmed
pubmed-article:1601822pubmed:ownerNLMlld:pubmed
pubmed-article:1601822pubmed:authorsCompleteYlld:pubmed
pubmed-article:1601822pubmed:pagination43-8lld:pubmed
pubmed-article:1601822pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:1601822pubmed:meshHeadingpubmed-meshheading:1601822-...lld:pubmed
pubmed-article:1601822pubmed:meshHeadingpubmed-meshheading:1601822-...lld:pubmed
pubmed-article:1601822pubmed:meshHeadingpubmed-meshheading:1601822-...lld:pubmed
pubmed-article:1601822pubmed:meshHeadingpubmed-meshheading:1601822-...lld:pubmed
pubmed-article:1601822pubmed:meshHeadingpubmed-meshheading:1601822-...lld:pubmed
pubmed-article:1601822pubmed:meshHeadingpubmed-meshheading:1601822-...lld:pubmed
pubmed-article:1601822pubmed:meshHeadingpubmed-meshheading:1601822-...lld:pubmed
pubmed-article:1601822pubmed:meshHeadingpubmed-meshheading:1601822-...lld:pubmed
pubmed-article:1601822pubmed:meshHeadingpubmed-meshheading:1601822-...lld:pubmed
pubmed-article:1601822pubmed:meshHeadingpubmed-meshheading:1601822-...lld:pubmed
pubmed-article:1601822pubmed:meshHeadingpubmed-meshheading:1601822-...lld:pubmed
pubmed-article:1601822pubmed:meshHeadingpubmed-meshheading:1601822-...lld:pubmed
pubmed-article:1601822pubmed:meshHeadingpubmed-meshheading:1601822-...lld:pubmed
pubmed-article:1601822pubmed:meshHeadingpubmed-meshheading:1601822-...lld:pubmed
pubmed-article:1601822pubmed:meshHeadingpubmed-meshheading:1601822-...lld:pubmed
pubmed-article:1601822pubmed:meshHeadingpubmed-meshheading:1601822-...lld:pubmed
pubmed-article:1601822pubmed:meshHeadingpubmed-meshheading:1601822-...lld:pubmed
pubmed-article:1601822pubmed:year1992lld:pubmed
pubmed-article:1601822pubmed:articleTitleAML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes.lld:pubmed
pubmed-article:1601822pubmed:affiliationDepartment of Hematology, University of Texas M.D. Anderson Cancer Center, Houston 77030.lld:pubmed
pubmed-article:1601822pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1601822pubmed:publicationTypeCase Reportslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1601822lld:pubmed